The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

18 May 2022 12:06

RNS Number : 9686L
MGC Pharmaceuticals Limited
18 May 2022
 

MGC Pharmaceuticals Ltd.

PDMR Notification

18 May 2022

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.

The shares the subject of this notice were issued to the PDMR in accordance with a Share Purchase Agreement executed by MGC Pharma and the owners of MediCaNL Inc in April 2021, with the issued shares being the final tranche of deferred consideration payable by MGC Pharma to the PDMR who was a shareholder of MediCaNL Inc.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Nadya Lisovoder

2

Reason for the notification

 

(a)

Position

 

Chief Medical Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Full name of entity

MGC Pharmaceuticals Limited

 

Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU000000MXC6

(c)

Nature of transaction

Shares issued as consideration for a corporate entity acquired by the Issuer.

(d)

Currency

Price

Volume

Total

AUD

$0.067

6,721,179

450,319

Aggregated information

AUD

$0.067

6,721,179

450,319

(e)

Date of transaction

 

2022-05-13

(f)

Place of transaction

 

Outside a trading venue

 

--Ends--

 

Authorised for release by the Executive Chair, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDUSGBDGDI
Date   Source Headline
28th Sep 20224:35 pmRNSPrice Monitoring Extension
28th Sep 20227:00 amRNSContravention of the TGA Advertising Code
23rd Sep 20227:00 amRNSUS$550,000 funding received under Mercer Facility
21st Sep 20227:00 amRNSCimetrA™ Dose Finding Study Interim Results
8th Sep 202212:47 pmRNSWebsite / Social Media update
6th Sep 202211:30 amRNSDispatch of General Meeting Documents
1st Sep 20227:00 amRNSPreliminary Financial Report for 30 June 2022
25th Aug 20227:00 amRNSFinal Payment for Malta GMP Manufacturing Plant
17th Aug 20227:00 amRNSAMC Holdings, Inc. places US$1M ArtemiC™ order
15th Aug 20227:00 amRNSCannEpil® Clinical Study on Driving Performance
11th Aug 202211:05 amRNSSecond Price Monitoring Extn
11th Aug 202211:00 amRNSPrice Monitoring Extension
8th Aug 202210:30 amRNSUpdated Investor Presentation
3rd Aug 20227:00 amRNSFirst Tranche of Mercer Street Funding Received
29th Jul 20227:00 amRNSUS$10m Financing Agreement with Mercer Street
28th Jul 20227:45 amRNSPurchase of Strategic 40% Stake in AI Software
25th Jul 20227:00 amRNSJune Quarterly Activities Report and Cash Flow
19th Jul 20227:00 amRNSChief Commercial Officer Appointment
14th Jul 20224:41 pmRNSSecond Price Monitoring Extn
14th Jul 20224:36 pmRNSPrice Monitoring Extension
14th Jul 20222:05 pmRNSSecond Price Monitoring Extn
14th Jul 20222:00 pmRNSPrice Monitoring Extension
14th Jul 202211:05 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
14th Jul 20229:05 amRNSSecond Price Monitoring Extn
14th Jul 20229:00 amRNSPrice Monitoring Extension
14th Jul 20227:16 amRNSClinical Study results - patients with Long COVID
8th Jul 20227:00 amRNSApproval Granted for CimetrA Dose Finding Study
6th Jul 20228:00 amRNSLaunch of ZAM - Medical data App
27th Jun 20227:00 amRNSCimetrATM Pre-clinical Trial Progress Report
24th Jun 20227:00 amRNSUSA Market Update: CimetrA Clinical Trial Progress
16th Jun 20227:00 amRNSSuccessful Glioblastoma Pre-clinical Trial Results
6th Jun 20227:00 amRNSCogniCann© Phase II Clinical Trial Results
27th May 20221:08 pmRNSCompliance Filing of UK subsidiary FY21 Accounts
23rd May 202210:43 amRNSApplication for Admission to Trading
20th May 20227:00 amRNSAcademic Paper on Effect of ArtemiC™ Published
18th May 202212:06 pmRNSDirector/PDMR Shareholding
10th May 20227:01 amRNSCannEpil® Drug Delivery System Patent Approval
9th May 202212:28 pmRNSDirector/PDMR Shareholding
6th May 20223:08 pmRNSReplacement: Director/PDMR Shareholding
5th May 202211:10 amRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSPartnership with HempStreet
29th Apr 20224:41 pmRNSSecond Price Monitoring Extn
29th Apr 20224:35 pmRNSPrice Monitoring Extension
29th Apr 202210:03 amRNSMarch Quarterly Activities Report and Cash Flow
26th Apr 20227:00 amRNSAppointment of new Chief Financial Officer
25th Apr 202211:08 amRNSApplication for Admission to Trading
21st Apr 20227:00 amRNSCimetrA™ Patent Approved by European IP Office
12th Apr 20228:36 amRNSPerformance Rights and Change of CFO
7th Apr 202210:35 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.